HomeCompareBMY vs RTX

BMY vs RTX: Dividend Comparison 2026

BMY yields 4.17% · RTX yields 1.45%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $86.7K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
RTX
RTX
● Live price
1.45%
Share price
$187.15
Annual div
$2.72
5Y div CAGR
32.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.8K
Annual income
$3,684.67
Full RTX calculator →

Portfolio growth — BMY vs RTX

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYRTX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + RTX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
RTX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
RTX
Annual income on $10K today (after 15% tax)
$123.54/yr
After 10yr DRIP, annual income (after tax)
$3,131.97/yr
At 15% tax rate, BMY beats the other by $30,718.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + RTX for your $10,000?

BMY: 50%RTX: 50%
100% RTX50/50100% BMY
Portfolio after 10yr
$77.2K
Annual income
$21,754.17/yr
Blended yield
28.19%
📊

Analyst Conviction Gap

Where Wall Street is split right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
RTX
Analyst Ratings
17
Buy
9
Hold
Consensus: Buy
Price Target
$219.20
+17.1% upside vs current
Range: $168.00 — $240.00
Altman Z
2.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
RTX buys
0
No recent congressional trades found for BMY or RTX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYRTX
Forward yield4.17%1.45%
Annual dividend / share$2.49$2.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%32.4%
Portfolio after 10y$120.5K$33.8K
Annual income after 10y$39,823.66$3,684.67
Total dividends collected$91.0K$12.1K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusHoldBuy
Analyst price target$62.73$219.20

Year-by-year: BMY vs RTX ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrRTX PortfolioRTX Income/yrGap
1← crossover$11,271$571.12$10,892$192.43+$379.00BMY
2$12,884$824.20$11,914$259.36+$970.00BMY
3$14,993$1,206.32$13,099$351.03+$1.9KBMY
4$17,839$1,797.27$14,494$477.56+$3.3KBMY
5$21,826$2,738.11$16,162$653.83+$5.7KBMY
6$27,643$4,289.31$18,196$902.17+$9.4KBMY
7$36,534$6,955.64$20,726$1,256.79+$15.8KBMY
8$50,861$11,770.13$23,948$1,771.40+$26.9KBMY
9$75,402$20,980.23$28,157$2,532.66+$47.2KBMY
10$120,504$39,823.66$33,813$3,684.67+$86.7KBMY

BMY vs RTX: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

RTXIndustrials

RTX Corporation, an aerospace and defense company, provides systems and services for the commercial, military, and government customers in the United States and internationally. It operates through three segments: Collins Aerospace, Pratt & Whitney, and Raytheon. The Collins Aerospace Systems segment offers aerospace and defense products, and aftermarket service solutions for civil and military aircraft manufacturers and commercial airlines, as well as regional, business, and general aviation, defense, and commercial space operations. This segment also designs, produces, and supports cabin interior, including oxygen systems, food and beverage preparation, storage and galley systems, and lavatory and wastewater management systems; battlespace, test and training range systems, crew escape systems, and simulation and training solutions; information management services; and aftermarket services that include spare parts, overhaul and repair, engineering and technical support, training and fleet management solutions, and asset and information management services. Its Pratt & Whitney segment supplies aircraft engines for commercial, military, business jet, and general aviation customers; and produces, sells, and services military and commercial auxiliary power units. The Raytheon segment provides defensive and offensive threat detection, tracking, and mitigation capabilities for U.S., foreign government, and commercial customers. The company was formerly known as Raytheon Technologies Corporation and changed its name to RTX Corporation in July 2023. RTX Corporation was incorporated in 1934 and is headquartered in Arlington, Virginia.

Full RTX Calculator →
📬

Get this BMY vs RTX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.